Open AccessKilling of human leukaemia/lymphoma B cells by activated cytotoxic T lymphocytes in the presence of a bispecific monoclonal antibody (αCD3/αCD19)
Author(s) -
HAAGEN I. A.,
GRIEND R.,
CLARK M.,
GEERARS A.,
BAST B.,
GAST B. de
Publication year - 1992
Publication title -
clinical & experimental immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.329
H-Index - 135
eISSN - 1365-2249
pISSN - 0009-9104
DOI - 10.1111/j.1365-2249.1992.tb05853.x
Subject(s) - cytotoxic t cell , cd19 , antigen , cd3 , immunology , biology , monoclonal antibody , peripheral blood mononuclear cell , antibody , t cell , b cell , microbiology and biotechnology , immune system , cd8 , in vitro , biochemistry
SUMMARY Bispecific antibodies (BsAb) can be used to retarget T cells irrespective of their specificity to certain target cells inducing target cell lysis. We have tested the efficacy of the BsAb SHR‐1, directed against the T cell antigen CD3 and the B cell antigen CD 19 to induce (malignant) B cell kill by T cells as measured in a 51 Cr‐release assay. Two cytotoxic T cell clones (CTL). expressing TCRαβ or TCRγδ were effective in killing CD19 expressing B cell lines at different stages of differentiation in the presence, but not in the absence, of the BsAb. CDI9 target cells were not killed. Fresh CDI9* leukaemia/lymphoma cells were also efficiently killed by SHR‐1 preincubated CTL clones. In addition, phytohaemagglutinin (PHA) or CD.Vactivatcd IL‐2 expanded peripheral blood mono‐nuclear cells (PBMC) of normal donors did so after 2 weeks of stimulation. A concentration of 100 ng/ml of the BsAb was sufficient to obtain optimal lysis of all target cells tested. These results show that fresh human leukaemia/lymphoma cells, freshly derived from active lymphoblastic leukaemia (ALL) as well as non‐Hodgkin's lymphoma (NHL) patients, can be effectively killed in the presence of this BsAb by activated T cells.